Skip to main content

Fate Therapeutics Inc

FATE
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
SEC CIK
0001434316

In the last 90 days, Fate Therapeutics Inc insiders filed 0 open-market purchases and 2 sales; 156 institutions reported holding it in 13F filings for Q2 2026, worth $193.2M in total; no superinvestor holds it.

Q2 2026 vs. Q1 2026

How the institutions holding Fate Therapeutics Inc changed between Q1 2026 and Q2 2026.

All holders in Q2 2026All holders in Q1 2026

13F holders of FATE: Q1 2026 compared with Q2 2026
MeasureQ1 2026Of which not filed for Q2 2026Q2 2026Change
Holders1583156+1
Shares74.1M210.3K71.6M−2.32M (−3.1%)
Value$88.9M$252.4K$193.2M+$104.5M (+118.0%)

3 institutions that held it in Q1 2026 haven't filed for Q2 2026 yet. Not filing isn't selling, so the changes leave them out.

New holders (31)

Institutions that held Fate Therapeutics Inc at the end of Q2 2026 but not at the end of Q1 2026.

Sold out (30)

Institutions that held Fate Therapeutics Inc at the end of Q1 2026 and filed for Q2 2026 without it.

Not filed for Q2 2026 yet (3)

Institutions that held Fate Therapeutics Inc at the end of Q1 2026 and haven't filed a 13F for Q2 2026. Not filing isn't selling, so they aren't counted as sold out.

Institutions holding FATE in Q1 2026 that haven't filed for Q2 2026
InstitutionShares, Q1 2026Value, Q1 2026
CWM, LLC139,796$167.8K
Leo Wealth, LLC70,439$84.5K
Sunbelt Securities, Inc.91$109